2009 Fiscal Year Final Research Report
Molecular therapeutics targeting drug-resistance mechanisms
| Project/Area Number |
17016012
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research on Priority Areas
|
| Allocation Type | Single-year Grants |
|---|
| Review Section |
Biological Sciences
|
|---|
| Research Institution | Japanese Foundation For Cancer Research (2006-2009)
The University of Tokyo (2005) |
|---|
Principal Investigator |
TOMIDA Akihiro Japanese Foundation For Cancer Research, 癌化学療法センター ゲノム研究部, 部長 (40251483)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HAGA Naomi 財団法人癌研究会, 癌化学療法センターゲノム研究部, 研究員 (40376645)
RYOUHEI Katayama 財団法人癌研究会, 癌化学療法センター基礎研究部, 研究員 (60435542)
MASHIMA Tetsuo 財団法人癌研究会, 癌化学療法センター分子生物治療研究部, 研究員 (30311228)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SAKAMOTO Hiroshi 中外製薬鎌倉研究所, 創薬研究第二部
|
|---|
| Project Period (FY) |
2005 – 2009
|
| Keywords | 癌 / シグナル伝達 / ゲノム / 医療・福祉 / 薬学 |
|---|
| Research Abstract |
We studied molecular mechanisms of various types of drug resistance, such as apoptosis resistance, tumor microenvironment-associated drug resistance, PDK1-Akt-related cell survival signaling pathways, and telomere-mediated cell maintenance. We succeeded to identify new molecular targets and to discover compounds that inhibit such molecular targets. By evaluating the antitumor effect of such compounds, we accumulated fundamental information to develop new molecular-targeted therapy that controls drug resistance features of tumor cells.
|
Research Products
(34 results)
-
-
-
-
-
[Journal Article] PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation2009
Author(s)
Tanaka H, Hoshikawa Y, Oh-hara T, Koike S, Naito M, Noda T, Arai H, Tsuruo T, Fujita N.
-
Journal Title
Mol Cancer Res. 7
Pages: 557-69
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Casein kinase 2-interacting protein-1, a novel Akt pleckstrin homology domain-interacting protein, down-regulates PI3K/Akt signaling and suppresses tumor growth in vivo2007
Author(s)
Tokuda E, Fujita N, Oh-hara T, Sato S, Kurata A, Katayama R, Itoh T, Takenawa T, Miyazono K, Tsuruo T.
-
Journal Title
Cancer Res. 67
Pages: 9666-76
Peer Reviewed
-
-
-
-
[Journal Article] Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer2007
Author(s)
Saeki T, Nomizu T, Toi M, Ito Y, Noguchi S, Kobayashi T, Asaga T, Minami H, Yamamoto N, Aogi K, Ikeda T, Ohashi Y, Sato W, Tsuruo T.
-
Journal Title
J Clin Oncol. 25
Pages: 411-7
Peer Reviewed
-
-
-
[Journal Article] p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target2005
Author(s)
Mashima T, Oh-hara T, Sato S, Mochizuki M, Sugimoto Y, Yamazaki K, Hamada J, Tada M, Moriuchi T, Ishikawa Y, Kato Y, Tomoda H, Yamori T, Tsuruo T.
-
Journal Title
J Natl Cancer Inst. 97
Pages: 765-77
Peer Reviewed
-
-
-
-
-
-
-
-
-
